A


TNBC
PD-1
PD-L1
PD-L2
CTLA4
IDO1
IDO2
LAG3
TIGIT
p < 0.001
TCGA
GSE96058
Expression
Low
High

B


ER+/HER2-
PD-1
PD-L1
PD-L2
CTLA4
IDO1
IDO2
LAG3
TIGIT
p < 0.001
TCGA
Expression
Low
High



Figure S1. Association between the CYT score and expression of immune checkpoint molecules in TNBC, ER+/HER2-, and HER2+ breast cancer in the TCGA and GSE96058 cohorts. Box plots of immune checkpoint molecules; *PD-1, PD-L1, PD-L2, CTLA4, IDO1, IDO2, LAG3,* and *TIGIT* by low and high CYT score groups in (A) TNBC, (B) ER+/HER2-, and (C) HER2+ breast cancer. Mann Whitney U test was used to calculate *p* value. Median cut-off was used to divide two groups. TNBC, triple-negative breast cancer; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PD-1, programmed cell death 1; PD-L1, programmed cell death 1 ligand 1; PD-L2, programmed cell death 1 ligand 2; CTLA4, cytotoxic T-lymphocyte-associated protein 4; IDO1, indoleamine 1; IDO2, indoleamine 2; LAG3, lymphocyte activation gene 3; TIGIT, T cell immunoreceptor with Ig and ITIM domains.